Society for Immunotherapy of Cancer (SITC) 2022
Tradeshow/Conference
Boston Convention Centre, 415 Summer St., Boston, MA 02210Link
VISIT US AT BOOTH 711
The Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs (SITC 2022) provides a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.
NanoString Symposium: Expanding the Power of Spatial Biology
November 10, 11:40 a.m. – 1:10 p.m.
Room 157 at the Boston Exhibition and Convention Center
Spatial-omics Revolution: Innovation Roadmap and Key Applications
Vikram Devgan, PhD, Senior Director, Product Management, NanoString Technologies
Applications of the CosMx Spatial Molecular Imager
Joseph Beechem, PhD, Chief Scientific Officer and Senior Vice President of Research and Development, NanoString Technologies
Spatial Proteogenomics in the Era of Immunotherapy and COVID-19
Arutha Kulasinghe, PhD, NHMRC Research Fellow, The University of Queensland
Precision Oncology in Pancreatic Cancer through Single-cell and Spatial Omics
William Hwang, MD, PhD, Assistant Professor, Harvard Medical School; Principal Investigator, Massachusetts General Hospital; Associate Faculty Member, Broad Institute of MIT and Harvard
Sign up for an AtoMx Experience at our booth
Oral Presentations featuring NanoString Technologies
| ID | Time | Poster title | First author |
|---|---|---|---|
| 161 | November 10 11:55 a.m. to 12:55 p.m. | Single-Cell Spatial In situ Transcriptomics Unravels Vulvar HSIL Composition Associated with Complete Response to Therapeutic Vaccination | Ziena Abdulrahman |
| 951 | November 11 12:10 to 1:10 p.m. | Spatial Atlases of Immunological Development within the Lymph Node | Tyler Hether |
Poster Presentations featuring NanoString Technology
| ID | Time | Poster Title | First author |
|---|---|---|---|
| 25 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Potential Predictive Biomarkers for BXCL701 in Acute Myeloid Leukemia (AML) | Veena Agarwal |
| 99 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Spatial Insights into Tumor Immune Evasion Illuminated with the CosMx Spatial Molecular Imager Platform | Jason Reeves |
| 117 | November 10, 2022 11:40 a.m. to 1:10 p.m. | High-plex Spatial Proteomic Profiling of Immunotherapy Response Groups in Head and Neck Cancer Identifies Tissue Signatures Associated with Therapy Response | Arutha Kulasinghe |
| 127 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Spatial-specific Gene Signatures Outperform Bulk-mRNA Signatures to Define Resistance to Immunotherapy in Melanoma Patients | Thazin Aung |
| 133 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Spatially Defined Gene Signatures Uncover the Association of Extracellular Matrix Genes with Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma | Niki Gavrielatou |
| 147 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Comprehensive In Situ Immune Phenotyping with the CosMx High Plex Protein Assay | Tien M. Phan-Everson |
| 151 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Using Additional Morphology Markers in NanoString GeoMx Whole Transcriptome Atlas Assay to Assess NSCLC Tumor Subtype | Jessica Runyon |
| 161 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Single-cell Spatial In Situ Transcriptomics Unravels Vulvar HSIL Composition Associated with Complete Response to Therapeutic Vaccination | Ziena Abdulrahman |
| 167 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Comprehensive Profiling of Cancer-associated Fibroblasts in CD8+T Cell-exclusive Non-small Cell Lung Cancer Tumor Microenvironments Using the NanoString GeoMX Digital Spatial Profiler | Christina Cho |
| 289 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Clinical Expansion and Persistence of CAR T-cells: An Essential Biomarker in Need of Standardization | David Turicek |
| 513 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Overcoming Hedgehog Mediated ANTI-PD-1 Resistance in Melanoma through Prostaglandin Inhibition | Nicholas DeVito |
| 527 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Spatial Proteomic and Transcriptomic Biomarkers of Response to Immune Checkpoint Inhibitors in Operable Lung Cancer | Jonathan Stauber |
| 569 | November 10, 2022 11:40 a.m. to 1:10 p.m. | A CIVO Intratumor Microdose Phase 0 Trial of Subasumstat (TAK-981) in Combination with Cetuximab or Avelumab Reveals Type 1 Interferon Induction and Immune Activation in Head and Neck Cancer Patients | Jeffrey Houlton |
| 605 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-risk Resectable Melanoma (MEL): Final Phase II Clinical Trial Results | Arivarasan Karunamurthy |
| 867 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Deciphering of Radiotherapy-induced Immunomodulation Effect Synergized with Immunotherapy in Hepatocellular Carcinoma by Spatial Multi-omics Profiling | Mai Chan Lau |
| 869 | November 10, 2022 11:40 a.m. to 1:10 p.m. | NBTXR3-enhanced Proton Beam Immunoradiotherapy Reshapes Tumor Immune Microenvironment and Improves Abscopal Effect in an Anti-PD1-resistant Lung Cancer | Yun Hu |
| 899 | November 10, 2022 11:40 a.m. to 1:10 p.m. | BET Inhibitors Synergize with Anti-PD1 by Enhancing TCF7 Accessibility in Leukemiaderived Terminally Exhausted CD8+ T Cells | Kyle Romine |
| 913 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Translational Analysis of Advanced Metastatic Bladder Cancer Patients Treated With IO Combination Maveropepimut-S, Cyclophosphamide, and Pembrolizumab | Heather Torrey |
| 923 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Deep Single-cell, Proteogenomic Insights from SARS-CoV-2 Infected Lung Tissues | Arutha Kulasinghe |
| 951 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Spatial Atlases of Immunological Development within the Lymph Node | Tyler Hether |
| 1151 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Revealing Novel Therapeutic Indications through Profiling of Immune Modulatory Properties by Uliledlimab | Yanni Zhang |
| 1165 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Impact of SD-101, a Toll-like Receptor 9 Class C (TLR9C), Agonist on Myeloid Derived Suppressor Cells | Chandra Ghosh |
| 1169 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Systemic Administration of TLR7/8 Agonist Micelles Triggers a Potent Anti-tumor Response Mediated by Neutrophils as Primary Effector Cells Followed by Establishment of an Immune Memory Response | Simon Jensen |
| 1173 | November 10, 2022 11:40 a.m. to 1:10 p.m. | ST101, a Peptide Antagonist of Novel I/O Target CEBPβ, Reprograms MDSC Polarization and Decreases Tumor-associated Tregs, Suggesting an Immune Component to Observed Clinical Responses | Claudio Scuoppo |
| 1337 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Preclinical Evaluation of STAR0602, a Novel, First-in-class Anti-TCR Vb Targeted Bispecific Antibody with Potent Anti-tumor Activity for PD-1 Refractory Solid Tumors | Zhen Su |
| 1451 | November 10, 2022 11:40 a.m. to 1:10 p.m. | The Impact of the Tumor Microenvironment on B Cell Infiltrate and Tertiary Lymphoid Structures in High Grade Serous Ovarian Cancer Patients | Ian MacFawn |
| 1467 | November 10, 2022 11:40 a.m. to 1:10 p.m. | An Holistic and Intergrated Approach for Investigating the Bacterial Microbiome, Gene Expression Profile and Immune Cell Profile in the Non-muscle Invasive Bladder Cancer Tumour Microenvironment | Tyler Wooldridge |
| 1471 | November 10, 2022 11:40 a.m. to 1:10 p.m. | Pharmacodynamic and Predictive Biomarkers Associated with Response in Cancer Patients Treated with TPST-1120: A First-in-class, Small Molecule Antagonist of Peroxisome-proliferator Activated Receptor-Alpha | Nathan Standifer |
| 76 | November 11, 2022 11:55 a.m. to 1:25 p.m. | NGS-based Immunology Panel: Applications in Preclinical Immuno-oncology Research | Jia Xue |
| 102 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Exploring the Spatial Heterogeneity of Immune Cells in Nasopharyngeal Tumours | Aastha Sobti |
| 110 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Characterization of HPV-specific T-cells in Blood and Tissue in Ugandan Women Living with HIV with Cervical Low Grade Squamous Intraepithelial Lesions | Amy Codd |
| 118 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Delineation of Spatial Tissue Signatures of Immunotherapy Response Groups in Non-small Cell Lung Cancer (NSCLC) | Arutha Kulasinghe |
| 142 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Demonstrating the Role of Spatial Contexture in Determining Response to Immune Check Point Inhibitors Using a Tumor Histoculture Platform | Satish Sankaran |
| 360 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Novel Immunotherapy for Prostate Cancer Combining CAR T Cells and Myeloid Cell STAT3 Inhibition | John Murad |
| 390 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Digital Spatial Profiling and Antigen-dependent Phenotypic Analysis of IL15-engineered Tumor-infiltrating Lymphocytes (CytoTIL15 Therapy) in an Allogeneic Melanoma PDX Model | Rachel Burga |
| 424 | November 11, 2022 11:55 a.m. to 1:25 p.m. | An Allosteric, Orally Administered CBL-B Inhibitor Remodels the Tumor Microenvironment and Enhances Immune-mediated Tumor Growth Inhibition | Yilin Qi |
| 428 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Diffusing Alpha-emitters Radiation Therapy Promotes a Pro-immunogenic Tumor Microenvironment and Synergizes with Pd-1 Blockade | Sara Roumani |
| 438 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Interrogation of Immune Toxicity in Patients with Thymic Epithelial Tumors (TETS) | Meredith McAdams |
| 492 | November 11, 2022 11:55 a.m. to 1:25 p.m. | SIRPa Blockade Results in Tumor Intrinsic and Immune Microenviroment Effects Resulting in the Inhibition of Breast-to-brain Metastatsis | Elizabeth Stirling |
| 504 | November 11, 2022 11:55 a.m. to 1:25 p.m. | PVRIG, a Novel T Cell Checkpoint, is Preferentially Expressed in TLS on Stem-like Memory T Cells, Potentially Inhibiting their Expansion | Zoya Alteber |
| 566 | November 11, 2022 11:55 a.m. to 1:25 p.m. | ENTPD1 as Predictive Marker of Treatment Response to Gemogenovatucel-T (Vigil) in Newly Diagnosed Ovarian Cancer | Rodney Rocconi |
| 610 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Immune Biomarker Analysis of RP1 in Combination with Nivolumab in Patients with Advanced Solid Tumors | Kevin Harrington |
| 720 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Enhancing the Anti-tumor Immunity and Therapeutic Potential of ICT01, a Butyrophilin3A-targeted, γ9δ2 T Cell-activating Monoclonal Antibody, with Low Dose IL-2 in Patients with Advanced Solid Tumors: The Eviction-2 Trial | Johann De Bono |
| 784 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Immune Profiling of Patients with Advanced Melanoma Intratumorally Treated with CV8102 as a Single-agent or in Combination with Anti-PD-1 Antibodies – Results of a Phase I Trial Expansion | Marina Gonzalez |
| 840 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Triple-drug Oral Immunotherapy Targeting Myeloid Cells for Treatment of Metastatic Osteosarcoma Evaluated in Spontaneous Canine Model | Cheryl London |
| 850 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Interim Results for Phase 1B Dose Expansion of MTL-CEBPA in Combination with Pembrolizumab in Patients with Advanced Solid Tumour Malignancies | Ruth Plummer |
| 990 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Heterogeneity in Glioblastoma Tumor Microenvironment: Strategies for Cancer-associated Fibroblast Targeting | Jonathan Stauber |
| 1076 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Anchored Immunotherapy with Intratumorally Administered Aluminum Hydroxide-tethered IL-12 Induces Potent Anti-tumor Immune Response | Sailaja Battula |
| 1136 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Induction of Tertiary Lymphoid Structures in Non-small Cell Lung Cancer Improves B and T Cell Anti-tumor Immunity | Hye Mi Kim |
| 1218 | November 11, 2022 11:55 a.m. to 1:25 p.m. | MSLN-targeted Immunotoxin LMB-100 Induces Development of Tertiary Lymphoid Structures and Tumor Regressions of Orthotopic Mesothelioma | Wenlong Liu |
| 1316 | November 11, 2022 11:55 a.m. to 1:25 p.m. | A Novel Class of T Cell-activating Antibody that Selectively Targets the TCR B Chain to Promote Antitumor Activity through Activation and Expansion of a Novel, Polyclonal Effector Memory T Cell Subset | Andy Bayliffe |
| 1340 | November 11, 2022 11:55 a.m. to 1:25 p.m. | BT7455, a Fully Synthetic Bicycle Tumor-targeted Immune Cell Agonist, Leads to Potent EphA2-dependent CD137 Agonism and Robust Anti-tumor Efficacy | Kristen Hurov |
| 1356 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Transcriptional Profiling of Bicycle Tumor-targeted CD137 Agonist-treated Mouse Tumors Revealed an Early and Rapid Activation of Myeloid Cells Followed by Infiltration of Cytotoxic T Cells into the Tumor | Johanna Lahdenranta |
| 1430 | November 11, 2022 11:55 a.m. to 1:25 p.m. | The Immunological and Genomic Profiling of Colorectal and Breast Cancer Cell Lines can Distinguish Stem Like from Differentiated Tumor Cells: Implications for Cancer Immunotherapy | Neha Gopinath |
| 1434 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Interplay between the Tumour and Gut Microbiome and the Tumour Immune Microenvironment in Complete Responder Cancer Patients | Nicola Annels |
| 1448 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Altered Myeloid Memory Function by BMP Signaling in Breast Cancer Bone Metastases | Claire Ihle |
| 1454 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Multiomics and Multimodal Analysis Approach to Construct a Diffuse Large B Cell Lymphoma Atlas of Tumor Microenvironment for Predictive Modeling | Mike Mattie |
| 1456 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Characterization of Inter and Intra Tumor Heterogeneity in Primary Melanoma and Melanoma Brain Metastases | Alberto Mendoza Valderrey |
| 1458 | November 11, 2022 11:55 a.m. to 1:25 p.m. | Regulation of Neoantigen Specific T Cell Infiltration and Spatial Tumor Immune Architecture of Myeloma and its Premalignant Precursors | Nancy Villa |
| 1468 | November 11, 2022 11:55 a.m. to 1:25 p.m. | First Data Readout of Standardized Transcriptional Profiling for Optimizing Cellular Therapies: A Multi-center PICI-NanoString Collaboration | Sarah Church |
| 1478 | November 11, 2022 11:55 a.m. to 1:25 p.m. | A Phase I Study of Personalized Adoptive TCR T Cell Therapy in Patients with Solid Tumors: Safety, Efficacy, and T Cell Trafficking to Tumors of Non-virally Gene Edited T Cells | Susan Foy |
Related Content
